Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
To book your Sofwave consultation, call +44 (0)141 370 0509 or request an appointment online
Maximum doses are safety ceilings, not goals, and many patients see results without reaching the highest dose
ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
The triple-receptor approach: how retatrutide targets GLP-1, GIP, and glucagon Retatrutide takes a fundamentally different approach
This is the body's natural, endogenous version of popular GLP-1 receptor agonist medications
US$ 24.50
US$ 22.32
US$ 21.18
US$ 23.21
US$ 27.81
US$ 22.27
